酒精相关性肝炎合并急性肾损伤患者的结局——来自HRS Harmony联盟的结果
该回顾性队列研究纳入11个医院网络2019年连续收治的2062例肝硬化合并急性肾损伤(AKI)成人患者,其中303例(15%)符合NIAAA标准的酒精相关性肝炎(AH)。AH组90天累积死亡率45%(95%CI:39%-51%)高于非AH组的38%(95%CI:35%-40%),但校正MELD-Na、年龄和性别后差异不再显著;在肝肾综合征患者中,AH是90天死亡率的独立预测因素(sHR:1.82,95%CI:1.16-2.86,p=0.009)。
要点
- 肝硬化合并AKI患者中,AH组90天累积死亡率45%(95%CI:39%-51%),非AH组38%(95%CI:35%-40%),p=0.026。
- 校正MELD-Na、年龄和性别后,AH与90天死亡率关联未达统计学显著。
- 在肝肾综合征患者中,AH是90天死亡率的独立预测因素(sHR:1.82,95%CI:1.16-2.86,p=0.009)。
核心结论
- 住院肝硬化合并AKI患者中,合并AH者90天死亡率高于不合并AH者,但这一差异可能由更高的MELD-Na驱动而非AH本身。
- 在肝肾综合征患者中,AH是死亡率的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入11个医院网络2019年连续收治的肝硬化合并AKI成人患者2062例。
- 其中303例(15%)符合美国国家酒精滥用与酒精中毒研究所(NIAAA)标准的AH。
- 比较AH组与非AH组的AKI表型、临床病程和结局。
主要发现
- AH组患者较非AH组更年轻,入院时MELD-Na评分更高。
- 两组AKI表型显著不同(p < 0.001),急性肾小管坏死在AH组更常见。
- AH组达到更严重的峰值AKI分期,需要更多肾脏替代治疗。
- AH组90天累积死亡率45%(95%CI:39%-51%),非AH组38%(95%CI:35%-40%),p = 0.026。
- 以无AH为参照,AH组90天死亡率未校正sHR为1.24(95%CI:1.03-1.50),p = 0.024,校正MELD-Na、年龄和性别后不显著;在肝肾综合征患者中,AH是90天死亡率的独立预测因素(sHR:1.82,95%CI:1.16-2.86,p = 0.009)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The development of acute kidney injury (AKI) in the setting of alcohol-associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown. METHODS: Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non-AH groups. RESULTS: A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End-stage Liver Disease-Sodium (MELD-Na) scores on admission. AKI phenotypes significantly differed between groups (p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90-day cumulative incidence of death (45% [95% CI: 39%-51%] vs. 38% [95% CI: 35%-40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90-day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03-1.50], p = 0.024), but was not significant when adjusting for MELD-Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90-day mortality (sHR: 1.82 [95% CI: 1.16-2.86], p = 0.009). CONCLUSIONS: Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90-day mortality than those without AH, but this may have been driven by higher MELD-Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.
引用
- Ma AT, Allegretti AS, Cullaro G, et al. Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium. Aliment Pharmacol Ther. 2024. PMID: 39010302. doi:10.1111/apt.18159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。